Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

N/A

28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

10.1016/j.jaad.2021.06.723 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB177

Author(s):

Andrew Blauvelt ◽

Andreas Wollenberg ◽

Andrew Pink ◽

Ketty Peris ◽

April Armstrong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.9 ◽

2021 ◽

Vol 5 (1) ◽

pp. s9

Author(s):

Jonathan Silverberg ◽

Sebastien Barbarot ◽

Melinda Gooderham ◽

Jan Simon ◽

Eric Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal study

European Psychiatry ◽

10.1016/s0924-9338(14)78034-4 ◽

2014 ◽

Vol 29 ◽

pp. 1 ◽

Cited By ~ 3

Author(s):

J. Newcorn ◽

V. Harpin ◽

M. Huss ◽

M. Johnson ◽

J.A. Ramos-Quiroga ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Attention Deficit ◽

Extended Release ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Hyperactivity Disorder ◽

Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.11 ◽

2021 ◽

Vol 5 (1) ◽

pp. s11

Author(s):

Eric Simpson ◽

Joseph Merola ◽

Jonathan Silverberg ◽

Rebecca Zachariae ◽

Rebecca Olsen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Adult Patients ◽

Phase 2 ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Efficacy of proactive long‐term maintenance therapy of canine atopic dermatitis with 0.0584% hydrocortisone aceponate spray: a double‐blind placebo controlled pilot study

Veterinary Dermatology ◽

10.1111/vde.12285 ◽

2016 ◽

Vol 27 (2) ◽

pp. 88 ◽

Cited By ~ 12

Author(s):

Ana M. Lourenço ◽

Vanessa Schmidt ◽

Berta São Braz ◽

Diana Nóbrega ◽

Telmo Nunes ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pilot Study ◽

Maintenance Therapy ◽

Double Blind ◽

Canine Atopic Dermatitis ◽

Double Blind Placebo ◽

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

10.1016/j.jaad.2021.06.402 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB96

Author(s):

David Rosmarin ◽

Scott Fretzin ◽

Lindsay Strowd ◽

Marta Casillas ◽

Amy DeLozier ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Rapid Improvement ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Skin Pain

15057 Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2)

10.1016/j.jaad.2020.06.199 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB28

Author(s):

Kristian Reich ◽

Jean Philippe Lacour ◽

Antonio Costanzo ◽

Dennis R. Brinker ◽

Maria Jose Rueda ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Pooled Data

Prevalence of comorbidities with peanut allergy: results from two phase 3, randomized, double-blind, placebo-controlled trials (PALISADE and RAMSES)

World Allergy Organization Journal ◽

10.1016/j.waojou.2020.100296 ◽

2020 ◽

Vol 13 (8) ◽

pp. 100296

Author(s):

Kirsten Beyer ◽

Alan Goldsobel ◽

Douglas Johnston ◽

Noelle M. Griffin ◽

Kari R. Brown ◽

...

Keyword(s):

Peanut Allergy ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo